January 8, 2017 | Clal Biotechnology Industries Ltd. announced today that Neon Therapeutics had completed a $70 million financing round. Following the round, Clal Biotechnology will own 5% of US company Neon. The round was led by Partner Fund Management, together with Inbio, Wellington, Fidelity Ventures, and Nextech Invest. Previous investors Third Rock Ventures and Access Industries also took part. Neon has begun a trial of a vaccination against malaria. Clal Biotechnoloigy was founded in 1998 and is based out of Ramat Gan, Israel.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments